PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty ...

Zusduri demonstrated a 72.2% 24-month response durability in LG-IR-NMIBC patients, leading to FDA approval as a non-surgical treatment option. The ENVISION trial enrolled 240 patients, focusing on ...

UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) UroGen Pharma Ltd ...

Presents 18-month duration of response (DOR) data from the ENVISION study Analyzes the impact of tumor burden or focality in recurrent LG-IR-NMIBC, a substudy from ENVISION Reports ENVISION and ATLAS ...

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today ...

The benefit-risk profile was favorable, supporting UGN-102 mitomycin gel as a nonsurgical alternative to TURBT in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that adult patients ...

UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer UroGen (NASDAQ: URGN), a biotech company ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen (NASDAQ: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced ...